U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Drugs
  3. Development & Approval Process | Drugs
  4. Development Resources
  5. Cefepime – Injection products
  1. Development Resources

Cefepime – Injection products

Exceptions or additions to the recognized standards

For isolates of Enterobacterales with SDD susceptibility, use a dose of 2g every 8 hours in patients with normal renal function.

For Pseudomonas aeruginosa, use a dose of 2 g IV every 8 hours in patients with normal renal function.

For the bacteria listed below, susceptibility test interpretive criteria are not recognized at this time:

Acinetobacter spp

Other Non-Enterobacterales

Haemophilus influenzae and Haemophilus parainfluenzae

Neisseria gonorrhoeae

Back to Top